These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31754924)

  • 61. The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations.
    Acevedo R; Bai X; Borrow R; Caugant DA; Carlos J; Ceyhan M; Christensen H; Climent Y; De Wals P; Dinleyici EC; Echaniz-Aviles G; Hakawi A; Kamiya H; Karachaliou A; Lucidarme J; Meiring S; Mironov K; Sáfadi MAP; Shao Z; Smith V; Steffen R; Stenmark B; Taha MK; Trotter C; Vázquez JA; Zhu B
    Expert Rev Vaccines; 2019 Jan; 18(1):15-30. PubMed ID: 30526162
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands.
    Bos JM; Rümke H; Welte R; Postma MJ
    Clin Ther; 2003 Oct; 25(10):2614-30. PubMed ID: 14667962
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
    Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
    BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Epidemiology and economic burden of meningococcal disease in Germany: A systematic review.
    Gruhn S; Witte J; Greiner W; Damm O; Dietzsch M; Kramer R; Knuf M
    Vaccine; 2022 Mar; 40(13):1932-1947. PubMed ID: 35227520
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.
    Soriano-Gabarró M; Rosenstein N; LaForce FM
    J Health Popul Nutr; 2004 Sep; 22(3):275-85. PubMed ID: 15609780
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Efficacy, safety, and cost-effectiveness of meningococcal vaccines].
    Chinese Preventive Medicine Association
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Feb; 53(2):146-152. PubMed ID: 30744287
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.
    Hellenbrand W; Koch J; Harder T; Bogdan C; Heininger U; Tenenbaum T; Terhardt M; Vogel U; Wichmann O; von Kries R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1314-43. PubMed ID: 26487381
    [TBL] [Abstract][Full Text] [Related]  

  • 68. AMEND study protocol: a case-control study to assess the long-term impact of invasive meningococcal disease in Australian adolescents and young adults.
    Marshall H; McMillan M; Wang B; Booy R; Afzali H; Buttery J; Blyth CC; Richmond P; Shaw D; Gordon D; Barton B
    BMJ Open; 2019 Dec; 9(12):e032583. PubMed ID: 31888931
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review.
    Gibson E; Begum N; Sigmundsson B; Sackeyfio A; Hackett J; Rajaram S
    Hum Vaccin Immunother; 2016 May; 12(5):1202-16. PubMed ID: 26837602
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.
    Izquierdo G; Torres JP; Santolaya ME; Valenzuela MT; Vega J; Chomali M
    Hum Vaccin Immunother; 2015; 11(4):875-83. PubMed ID: 25714390
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Invasive meningococcal disease in the Czech Republic - analysis of the epidemiological situation and vaccination strategy recommendations].
    Křížová P; Vacková Z; Musílek M; Kozáková J
    Epidemiol Mikrobiol Imunol; 2013 Dec; 62(4):138-47. PubMed ID: 24467175
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model.
    Régnier SA; Huels J
    Hum Vaccin Immunother; 2014; 10(12):3737-45. PubMed ID: 25483706
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits.
    Stawasz A; Huang L; Kirby P; Bloom D
    Front Public Health; 2020; 8():261. PubMed ID: 32754566
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Experts' consensus on immunization with meningococcal vaccines in China].
    Chinese Preventive Medicine Association
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Feb; 53(2):141-145. PubMed ID: 30744286
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Experts' consensus on immunization with meningococcal vaccines in China].
    Chinese Preventive Medicine Association
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):123-128. PubMed ID: 30744259
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Vaccines for Prevention of Group B Meningococcal Disease: Not Your Father's Vaccines.
    Harrison LH
    Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S345-54. PubMed ID: 26590434
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Public health management of invasive meningococcal disease in Baden-Wuerttemberg, Germany, 2012: adherence to guidance and estimation of resources required as determined in a survey of local health authorities.
    Murajda L; Aichinger E; Pfaff G; Hellenbrand W
    BMC Public Health; 2015 Apr; 15():371. PubMed ID: 25881238
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysis.
    McMillan M; Chandrakumar A; Wang HLR; Clarke M; Sullivan TR; Andrews RM; Ramsay M; Marshall HS
    Clin Infect Dis; 2021 Aug; 73(3):e609-e619. PubMed ID: 33212510
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination.
    Burman C; Serra L; Nuttens C; Presa J; Balmer P; York L
    Hum Vaccin Immunother; 2019; 15(2):459-469. PubMed ID: 30273506
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.
    Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL
    Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.